Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2003 1
2004 1
2005 1
2006 4
2007 1
2008 1
2009 1
2010 3
2014 1
2015 1
2016 1
2018 1
2019 1
2020 8
2021 9
2022 9
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
[New immunotherapeutic approaches in oncology and hematology].
Kroemer M, Turco C, Galaine J, Deschamps M, Limat S, Borg C. Kroemer M, et al. Transfus Clin Biol. 2015 Aug;22(3):132-40. doi: 10.1016/j.tracli.2015.05.002. Epub 2015 Jun 9. Transfus Clin Biol. 2015. PMID: 26068883 Review. French.
CD8+ CD226high T cells in liver metastases dictate the prognosis of colorectal cancer patients treated with chemotherapy and radical surgery.
Viot J, Abdeljaoued S, Vienot A, Seffar E, Spehner L, Bouard A, Asgarov K, Pallandre JR, Renaude E, Klajer E, Molimard C, Monnien F, Bibeau F, Turco C, Heyd B, Peixoto P, Hervouet E, Loyon R, Doussot A, Borg C, Kroemer M. Viot J, et al. Among authors: kroemer m. Cell Mol Immunol. 2023 Apr;20(4):365-378. doi: 10.1038/s41423-023-00978-2. Epub 2023 Jan 30. Cell Mol Immunol. 2023. PMID: 36717657 Free PMC article.
Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.
Adotévi O, Vernerey D, Jacoulet P, Meurisse A, Laheurte C, Almotlak H, Jacquin M, Kaulek V, Boullerot L, Malfroy M, Orillard E, Eberst G, Lagrange A, Favier L, Gainet-Brun M, Doucet L, Teixeira L, Ghrieb Z, Clairet AL, Guillaume Y, Kroemer M, Hocquet D, Moltenis M, Limat S, Quoix E, Mascaux C, Debieuvre D, Fagnoni-Legat C, Borg C, Westeel V. Adotévi O, et al. Among authors: kroemer m. J Clin Oncol. 2023 Jan 10;41(2):373-384. doi: 10.1200/JCO.22.00096. Epub 2022 Sep 7. J Clin Oncol. 2023. PMID: 36070539 Clinical Trial.
Development of a biomimetic bioreactor for regenerative endodontics research.
Louvrier A, Kroemer M, Terranova L, Meyer F, Tissot M, Euvrard E, Gindraux F, Meyer C, Rolin G. Louvrier A, et al. Among authors: kroemer m. J Tissue Eng Regen Med. 2022 Nov;16(11):998-1007. doi: 10.1002/term.3346. Epub 2022 Aug 25. J Tissue Eng Regen Med. 2022. PMID: 36005295
Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation.
Couchoud C, Fagnoni P, Aubin F, Westeel V, Maurina T, Thiery-Vuillemin A, Gerard C, Kroemer M, Borg C, Limat S, Nerich V. Couchoud C, et al. Among authors: kroemer m. Cancer Immunol Immunother. 2020 Oct;69(10):1947-1958. doi: 10.1007/s00262-020-02646-0. Epub 2020 Jul 16. Cancer Immunol Immunother. 2020. PMID: 32676716 Free PMC article. Review.
45 results